PCOS Is Now PMOS: What the Rename Actually Means for You
After 14 years of work involving 56 organizations and more than 14,000 patients and clinicians, the condition formerly known as PCOS has a new name — and the change is more than semantic.
On May 12, 2026, a paper in The Lancet formally renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS). The change was the culmination of a 14-year global consensus process led by the International PCOS Network, involving 56 leading academic, clinical, and patient organizations and surveys of over 14,000 patients and health professionals.
If you have PCOS, you now have PMOS. Same condition. Same symptoms. But a fundamentally different framework for understanding — and treating — what's happening in your body.
Why the Old Name Was Wrong
The term "polycystic ovary syndrome" had three problems, and each one damaged patient care:
"Polycystic" implies the condition is defined by cysts on the ovaries. It isn't. The "cysts" visible on ultrasound are actually immature follicles — a normal variation that occurs in many women without the condition. Roughly 25% of healthy women have polycystic-appearing ovaries on ultrasound without having the syndrome. Meanwhile, many women with the full syndrome have normal-looking ovaries.
"Ovary" framed the condition as a reproductive disorder confined to the ovaries. It isn't. PMOS is a systemic metabolic and endocrine condition that affects insulin signaling, androgen production, cardiovascular risk, mental health, skin, hair, and body composition. Calling it an "ovary syndrome" directed clinical attention — and research funding — toward gynecology when endocrinology and metabolic medicine are equally relevant.
"Syndrome" stayed, because it remains a clinical syndrome defined by a cluster of features rather than a single pathological mechanism. That part was accurate.
What Each Word in PMOS Means
The new name was chosen because each word captures a dimension of the condition that the old name obscured:
Polyendocrine: Recognizes that the condition involves multiple interacting hormonal disturbances — not just ovarian hormones, but insulin, androgens, and neuroendocrine signaling. The "poly" applies to the hormonal systems involved, not to the number of cysts.
Metabolic: Acknowledges the inherent metabolic features — insulin resistance, increased risk for type 2 diabetes and cardiovascular disease, disordered lipid metabolism, and visceral fat accumulation. These aren't complications of PMOS; they're core features. Women with PMOS are 50% more likely to develop insulin resistance compared to the general population.
Ovarian: Retains the connection to ovarian dysfunction, including ovulatory disturbances and fertility challenges, which remain defining features. The ovary isn't irrelevant — it's just not the whole story.
What Changes for Your Care
Your diagnostic criteria remain the same for now — the Rotterdam criteria (two of three: oligo/anovulation, clinical or biochemical hyperandrogenism, polycystic ovarian morphology) still apply. The rename doesn't change whether you qualify for a diagnosis.
What changes is the framing — and framing drives treatment.
Treatment implications of the metabolic reframe:
- Insulin resistance gets treated as a root cause, not a side effect. When the condition was "about ovaries," insulin resistance was treated as a secondary concern. Under the PMOS framework, addressing insulin signaling — through metformin, GLP-1 receptor agonists, inositol, or lifestyle intervention — is recognized as upstream therapy that can restore ovulation by fixing the metabolic dysfunction driving it.
- Cardiovascular screening becomes standard. PMOS carries elevated cardiovascular risk — higher rates of hypertension, dyslipidemia, and metabolic syndrome. The metabolic framing demands proactive screening rather than treating CVD risk as an unrelated finding.
- Mental health is built into the diagnosis. Anxiety, depression, and disordered eating are part of the PMOS clinical picture — not separate conditions that happen to co-occur. The endocrine name opens doors for integrated care.
- Peptide and GLP-1 therapies become easier to justify. Research on GLP-1 receptor agonists for PMOS was already growing rapidly. The metabolic reframe makes the clinical rationale explicit: these medications target the insulin resistance and metabolic dysfunction that the condition's own name now emphasizes.
The Peptide Connection
The rename arrives at a moment when peptide-based approaches to PMOS are generating the strongest evidence they've ever had. The metabolic reframe isn't just a label change — it creates a clinical framework where treating the metabolic root is standard practice.
| Peptide / Therapy | PMOS Target | Evidence Level |
|---|---|---|
| Semaglutide (GLP-1) | Insulin resistance, weight, androgen reduction, cycle regularity | Growing — RESTORE trial ongoing, 2026 studies positive |
| Tirzepatide (GIP + GLP-1) | Insulin resistance, body composition, metabolic health | Emerging — PMOS-specific data limited but mechanism fits |
| Kisspeptin-10 | Ovulation induction without hyperstimulation | Promising — Dhillo group research on anovulatory women |
| MOTS-C | Mitochondrial insulin sensitivity | Preclinical — mechanism aligns with PMOS insulin resistance |
| Myo-Inositol (supplement) | Insulin sensitization, ovulatory function | Established — first-line supplement, strong evidence base |
A 2026 study in Metabolism and Target Organ Damage found that approximately 87% of women with PMOS taking semaglutide combined with metformin saw their menstrual cycles normalize after 20 weeks, compared to 60% on metformin alone, with reductions in both insulin resistance and androgen levels. The ongoing RESTORE trial at the University of Colorado is evaluating semaglutide specifically for reproductive outcomes in PMOS — and early results prompted investigators to publish preliminary findings ahead of the full trial completion.
The key message: HRT addresses sex hormone deficiency. Peptides and GLP-1 therapies target the parallel axes — insulin signaling, metabolic function, neuroendocrine regulation — that estrogen replacement alone does not cover. The rename makes this distinction clinically visible for the first time.
What Doesn't Change
A few things to be clear about:
- Your diagnosis isn't revoked. If you were diagnosed with PCOS, you have PMOS. Same condition, new name. You don't need to be re-diagnosed.
- Existing treatments still apply. Metformin, oral contraceptives, spironolactone, lifestyle intervention — everything that worked under the PCOS name still works. The rename adds to the treatment framework; it doesn't replace what existed.
- Insurance coding will take time. ICD-10 codes and insurance documentation will transition gradually. Your provider may use both names during the transition period. This should not affect your coverage.
- Not everyone is happy about it. Some advocates wanted "ovarian" removed entirely, arguing it still centers the ovaries. Some researchers have suggested the condition may have a male form, which "ovarian" doesn't accommodate. The name was a consensus — no consensus satisfies everyone.
The Bottom Line
The rename from PCOS to PMOS is the biggest nomenclature change in women's endocrinology in decades. It corrects a 90-year-old misnomer, elevates the metabolic and endocrine dimensions of a condition that affects 170 million women, and creates clinical language that matches the emerging treatment landscape — one where insulin-targeting peptide therapies are generating real evidence.
For patients, the practical takeaway: if you have PMOS and your provider is only treating your symptoms (cycle regulation, acne management, fertility support), the rename gives you clinical language to ask about the metabolic root. Insulin resistance testing, cardiovascular screening, and metabolic interventions — including GLP-1 receptor agonists where appropriate — are part of the PMOS picture the new name demands.
The condition didn't change. The name did. And sometimes, naming something correctly is the first step toward treating it properly.